Paul Gagnier

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow, Jason Chesney, Anna C. Pavlick et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text

Life Sciences, Immunology, Oncology +17

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon, Charles G. Drake, H. I. Scher et al. · The Lancet Oncology · 2014 · 1.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

F. Stephen Hodi, Jason Chesney, Anna C. Pavlick et al. · The Lancet Oncology · 2016 · 980 citations

Medicine, Immunology, Oncology +17

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

Susan F. Slovin, Celestia S. Higano, Omid Hamid et al. · Annals of Oncology · 2013 · 550 citations · Full text

Medicine, Oncology, Pharmacology +14

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

Asim Amin, Elizabeth R. Plimack, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2014 · 231 citations

Medicine, Oncology, Pharmacotherapy +17